Fibroblast Activation Protein-Targeted PET Imaging of Metastatic Castration-Resistant Prostate Cancer Compared With 68Ga-PSMA and 18F-FDG PET/CT

Overview

Journal Clin Nucl Med

Specialty Nuclear Medicine

Date 2021 Aug 15

PMID 34392294

Citations 11

Authors

Emine Goknur Isik

Duygu Has-Simsek

Oner Sanli

Yasemin Sanli

Serkan Kuyumcu

Affiliations

Soon will be listed here.

Abstract

Herein we present 2 mCRPC (metastatic castration-resistant prostate cancer) patients who underwent 68Ga-PSMA PET/CT for PSMA-targeted radioligand therapy eligibility. Prior studies have noted aggressive clinical behavior and poor prognosis associated with discordant FDG positivity and low PSMA expression. Accordingly, the patients also underwent 18F-FDG PET/CT, which revealed intratumoral heterogeneity. Therefore, an additional PET/CT targeting fibroblast activation proteins (FAPs) using 68Ga-FAPI-04 was performed to assess the potential for an FAP-targeted therapy. This report highlights the theranostic potential of FAP imaging in mCRPC, particularly in patients with heterogeneous tumor phenotypes.

Citing Articles

Advancements in molecular imaging probes for precision diagnosis and treatment of prostate cancer.

Fang J, Alhaskawi A, Dong Y, Cheng C, Xu Z, Tian J J Zhejiang Univ Sci B. 2025; 26(2):124-144.

PMID: 40015933 PMC: 11867783. DOI: 10.1631/jzus.B2300614.

Design, preclinical evaluation, and first-in-human PET study of [Ga]Ga-PSFA-01: a PSMA/FAP heterobivalent tracer.

Wang X, Zhang X, Zhang X, Guan L, Gao X, Xu L Eur J Nucl Med Mol Imaging. 2024; 52(3):1166-1176.

PMID: 39520516 DOI: 10.1007/s00259-024-06965-7.

Detection of tumour heterogeneity in patients with advanced, metastatic castration-resistant prostate cancer on [Ga]Ga-/[F]F-PSMA-11/-1007, [Ga]Ga-FAPI-46 and 2-[F]FDG PET/CT: a pilot study.

Pabst K, Mei R, Luckerath K, Hadaschik B, Kesch C, Rawitzer J Eur J Nucl Med Mol Imaging. 2024; 52(1):342-353.

PMID: 39207485 PMC: 11599349. DOI: 10.1007/s00259-024-06891-8.

Is There a Role for FAPI PET in Urological Cancers?.

Ortolan N, Urso L, Zamberlan I, Filippi L, Buffi N, Cittanti C Mol Diagn Ther. 2024; 28(6):721-725.

PMID: 39181989 PMC: 11512897. DOI: 10.1007/s40291-024-00735-9.

Synthesis and Preclinical Evaluation of Two Novel Ga-Labeled Bispecific PSMA/FAP-Targeted Tracers with 2-Nal-Containing PSMA-Targeted Pharmacophore and Pyridine-Based FAP-Targeted Pharmacophore.

Verena A, Merkens H, Chen C, Chapple D, Wang L, Bendre S Molecules. 2024; 29(4).

PMID: 38398552 PMC: 10892057. DOI: 10.3390/molecules29040800.